BioRestorative Therapies, Inc.

BRTX

BioRestorative Therapies, Inc.

BRTX

Insider Sentiment (TTM):

Last Purchase:2024-04-09Last Sale:2024-10-28Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:677,096Shares Outstanding:17,727,747Institutional Ownership Pct.:3.82%

Earnings Market Reaction:

Filing Date:2026-05-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Services-Misc Health & Allied Services, NEC

DVA SHC PGNY VMD AGL PARK

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	3	2	1	2	1	1	1	2	1	1	2	2
Marketable Securities Current	0	1	4	6	8	10	12	12	15	10	10	10
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Offering Costs	-	-	-	-	-	-	0	-	-	-	-	-
Assets Current	4	3	5	8	9	11	14	15	17	11	13	12
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	-	-	-	-	-	-	0	0	0	0	0	0
Intangible Assets Net Excluding Goodwill	1	1	1	1	1	1	1	1	1	1	1	1
Deferred Costs	-	-	-	-	-	-	-	0	0	-	-	-
Assets	5	4	6	9	10	12	15	16	18	13	14	13
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	1	1	1	0	0	0	0	0	0	0
Other Accrued Liabilities Current	1	1	1	0	0	1	-	-	-	-	-	-
Accrued Liabilities Current	-	-	-	-	-	1	1	0	0	1	1	0
Deferred Revenue	-	-	-	-	-	-	-	0	-	-	-	-
Operating Lease Liability Current	-	-	-	-	-	-	0	0	0	0	0	0
Derivative Liabilities Current	-	1	2	3	3	3	3	4	3	2	-	-
Contract With Customer Liability Current	-	-	-	-	0	-	-	-	-	-	-	-
Liabilities Current	2	4	3	4	4	4	5	5	3	3	1	1
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities	-	-	-	4	4	4	5	5	3	3	1	1
Stockholders Equity
Preferred Stock Value	-	-	0	0	0	-	0	0	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	175	170	169	169	167	164	164	164	163	157	177	174
Retained Earnings Accumulated Deficit	-172	-170	-167	-164	-161	-156	-154	-153	-149	-147	-164	-161
Stockholders Equity	3	0	2	5	6	9	10	11	15	10	11	3
Liabilities And Stockholders Equity	5	4	6	9	10	12	15	16	18	13	14	13
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	225	225	225	225	225	225	225	225	225	225	225	225
Common Stock Shares Issued	25	27	24	24	23	21	21	21	20	19	19	20
Shares Outstanding	25	27	24	24	23	21	21	21	20	19	19	20

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	114.40%	111.75%	-	-	-	-	-	-	-	-	-	-
2025	5.56%	-9.36%	-17.54%	8.84%	2.04%	4.76%	-19.57%	-11.59%	-17.39%	-10.91%	-35.07%	19.09%
2024	59.83%	22.22%	40.17%	8.51%	15.46%	10.64%	-9.15%	-8.54%	45.12%	-3.31%	-11.05%	-7.18%
2023	-	-	-	-11.20%	-30.89%	-27.41%	0.08%	-4.93%	57.43%	-10.71%	-7.86%	45.00%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.35	0.84	1.37	2.07	2.24	2.97	2.95	2.82	4.86	4.37	13.51	14.82
Quick Ratio	2.23	0.80	1.31	2.01	2.19	2.91	2.90	2.76	4.77	4.25	13.17	14.32
Working Capital	2.19M	-586.03K	1.27M	3.93M	5.17M	7.40M	8.93M	9.68M	13.32M	8.78M	11.67M	11.23M
Leverage & Debt
Debt to Equity	0.53	10.44	1.56	0.76	0.68	0.44	0.46	0.49	0.24	0.26	0.09	0.34
Interest Coverage TTM	-85.57	-58.78	-41.39	-29.00	-22.14	-18.76	-13.84	-16.62	-19.45	-27.56	-57.09	-70.12
Debt Ratio	0.35	0.91	0.61	0.43	0.40	0.31	0.31	0.33	0.19	0.21	0.07	0.07
Efficiency & Turnover
Asset Turnover TTM	0.05	0.04	0.04	0.05	0.03	0.03	0.03	0.01	0.01	0.01	0.01	0.01
Days Sales Outstanding TTM	19.53	103.45	84.92	12.79	28.01	94.53	98.90	54.93	62.26	44.19	118.16	58.23
Receivables Turnover TTM	18.69	3.53	4.30	28.55	13.03	3.86	3.69	6.65	5.86	8.26	3.09	6.27
Per Share Metrics
Diluted EPS TTM	-0.62	-0.79	-0.69	-0.61	-0.72	-0.58	-0.59	-0.23	-0.41	-0.82	-0.58	-1.42
Free Cash Flow Per Share TTM	-0.67	-0.61	-0.59	-0.55	-0.53	-0.54	-0.47	-0.44	-0.32	-0.31	-0.29	-0.30
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	92.09%	93.37%	93.34%	94.51%	92.08%	93.00%	101.74%	114.25%	120.94%	-	-	-
Operating Profit Margin TTM	-3,975.00%	-4,350.05%	-3,785.07%	-2,162.91%	-3,133.88%	-2,881.59%	-3,205.76%	-7,411.36%	-9,064.17%	-10,439.49%	-12,812.59%	-14,153.50%
Net Profit Margin TTM	-3,089.55%	-3,959.40%	-3,304.77%	-1,771.91%	-3,093.59%	-2,239.25%	-2,558.95%	-2,175.50%	-3,657.78%	-7,145.20%	-5,521.34%	-12,928.31%
Growth Metrics
Net Revenue Growth (1Y)	-8.47%	-10.30%	1.70%	247.62%	161.54%	175.03%	189.55%	35.49%	10.66%	21.70%	7.51%	28.37%
Net Income Growth (1Y)	-8.59%	58.61%	31.34%	183.13%	121.20%	-13.81%	34.20%	-77.20%	-64.90%	-21.21%	-79.19%	-51.25%
EPS Growth (1Y)	-13.82%	36.93%	17.01%	163.08%	164.87%	17.08%	88.82%	-67.27%	-60.88%	-18.91%	-80.10%	-54.36%
Valuation Metrics
P/E TTM	-0.44	-1.48	-2.09	-2.72	-2.46	-2.47	-2.93	-8.71	-5.05	-3.52	-5.69	-6.19
P/B TTM	1.59	59.24	11.98	6.01	4.84	2.60	2.83	3.05	1.90	3.67	3.80	38.88
P/S TTM	13.48	58.75	68.95	48.11	76.09	55.37	74.97	189.39	184.75	251.70	314.20	800.25
Market Cap	4.82M	21.13M	26.44M	29.12M	29.75M	22.20M	28.26M	32.97M	27.62M	36.70M	40.91M	102.83M
Enterprise Value	1.71M	19.62M	25.83M	27.56M	28.52M	21.66M	26.77M	30.72M	26.46M	35.81M	38.47M	101.05M
Calculated Values
Free Cash Flow TTM	-11.90M	-10.91M	-10.77M	-9.63M	-8.83M	-8.34M	-7.63M	-7.07M	-6.48M	-6.60M	-6.60M	-6.89M
Net Debt	-3.11M	-1.51M	-602.44K	-1.56M	-1.23M	-547.89K	-1.49M	-2.25M	-1.16M	-884.38K	-2.44M	-1.78M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-10-28Sale

Owner: Broadrick, Dale

Title: -

Shares: 1,112

Price/Share: $1.58

Value: $1,756.96

Shares Owned: 445,933

Relationship: TenPercentOwner

Ownership: Direct

2024-04-09Purchase

Owner: Silva, Francisco

Title: VP of Research and Development

Shares: 6,600

Price/Share: $1.25

Value: $8,250.00

Shares Owned: 155,759

Relationship: Director,Officer

Ownership: Direct

2024-02-09Purchase

Owner: Broadrick, Dale

Title: -

Shares: 86,041

Price/Share: $1.32

Value: $113,574.12

Shares Owned: 477,972

Relationship: TenPercentOwner

Ownership: Indirect

2024-02-07Purchase

Owner: Broadrick, Dale

Title: -

Shares: 36,374

Price/Share: $1.38

Value: $50,196.12

Shares Owned: 363,419

Relationship: TenPercentOwner

Ownership: Direct

2023-12-01Sale

Owner: Broadrick, Dale

Title: -

Shares: 250

Price/Share: $1.88

Value: $470.00

Shares Owned: 327,045

Relationship: TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-10-28	Broadrick, Dale	TenPercentOwner	-	Direct	Sale	1,112	1.58	$1,756.96	445,933	4
2024-04-09	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Purchase	6,600	1.25	$8,250.00	155,759	4
2024-02-09	Broadrick, Dale	TenPercentOwner	-	Indirect	Purchase	86,041	1.32	$113,574.12	477,972	4
2024-02-07	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	36,374	1.38	$50,196.12	363,419	4
2023-12-01	Broadrick, Dale	TenPercentOwner	-	Direct	Sale	250	1.88	$470.00	327,045	4
2023-11-27	Broadrick, Dale	TenPercentOwner	-	Direct	Sale	278	1.89	$525.42	327,295	4
2023-09-15	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	10,000	1.66	$16,600.00	327,573	4
2023-09-15	Alstodt, Lance	Director,Officer,TenPercentOwner	President, CEO, COB	Direct	Purchase	2,200	1.70	$3,740.00	189,505	4
2023-09-13	Alstodt, Lance	Director,Officer,TenPercentOwner	President, CEO, COB	Direct	Purchase	800	1.53	$1,224.00	188,105	4
2023-09-07	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	1,000	1.81	$1,810.00	307,573	4
2023-09-06	Alstodt, Lance	Director,Officer,TenPercentOwner	President, CEO, COB	Direct	Purchase	2,887	1.96	$5,658.52	187,305	4
2023-08-31	Silva, Francisco	Director,Officer,TenPercentOwner	VP of Research and Development	Direct	Purchase	4,954	2.22	$10,997.88	164,644	4
2023-07-27	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	1,000	2.80	$2,800.00	306,073	4
2023-07-25	Alstodt, Lance	Director,Officer,TenPercentOwner	President, CEO, COB	Direct	Purchase	4,200	2.44	$10,248.00	184,418	4
2023-03-31	Silva, Francisco	Director,Officer,TenPercentOwner	VP of Research and Development	Direct	Purchase	747	3.56	$2,659.32	159,690	4
2023-02-22	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	6,000	2.90	$17,400.00	305,073	4
2023-02-01	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	400	3.10	$1,240.00	187,321	4
2023-01-27	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	200	3.01	$602.00	186,921	4
2023-01-20	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	200	3.14	$628.00	186,721	4
2023-01-18	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	400	3.11	$1,244.00	186,521	4
2023-01-09	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	100	3.08	$308.00	186,121	4
2022-12-23	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	300	3.00	$900.00	186,021	4
2022-12-07	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	1,800	2.99	$5,382.00	185,721	4
2022-11-21	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Purchase	943	2.62	$2,470.66	166,046	4
2022-11-18	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	1,000	2.88	$2,880.00	183,921	4
2022-10-12	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Purchase	725	3.39	$2,457.75	165,103	4
2022-10-11	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Purchase	806	3.69	$2,974.14	164,378	4
2022-09-23	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	300	2.83	$849.00	298,873	4
2022-09-22	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	200	2.92	$584.00	182,921	4
2022-08-29	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Purchase	2,816	3.21	$9,039.36	163,572	4
2022-08-26	Silva, Francisco	Director,Officer	VP of Research and Development	Direct	Sale	3,958	3.39	$13,417.62	158,156	4
2022-07-13	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	200	3.00	$600.00	298,573	4
2022-07-12	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	700	2.95	$2,065.00	182,721	4
2022-06-30	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	1,900	3.08	$5,852.00	297,373	4
2022-06-30	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	1,100	3.10	$3,410.00	182,021	4
2022-06-21	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	100	3.68	$368.00	295,473	4
2022-06-16	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	2,000	3.81	$7,620.00	294,773	4
2022-06-16	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	600	3.73	$2,238.00	180,921	4
2022-06-15	Kristal, Robert Eugene	Officer	Chief Financial Officer	Direct	Purchase	194	3.61	$700.34	7,994	4
2022-06-15	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	700	3.68	$2,576.00	180,321	4
2022-06-14	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	500	3.91	$1,955.00	179,621	4
2022-06-13	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	200	3.95	$790.00	179,121	4
2022-06-13	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	1,300	3.92	$5,096.00	291,573	4
2022-06-10	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	600	4.23	$2,538.00	290,273	4
2022-06-08	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	2,400	4.33	$10,392.00	288,673	4
2022-06-08	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	100	4.28	$428.00	178,921	4
2022-06-07	Kristal, Robert Eugene	Officer	Chief Financial Officer	Direct	Purchase	200	4.56	$912.00	7,800	4
2022-06-06	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	3,000	4.93	$14,790.00	282,673	4
2022-06-02	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	1,000	4.69	$4,690.00	278,473	4
2022-06-01	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	9,213	4.46	$41,089.98	277,473	4
2022-06-01	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	200	4.60	$920.00	178,821	4
2022-05-27	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	10,957	3.61	$39,554.77	268,260	4
2022-05-26	Broadrick, Dale	TenPercentOwner	-	Direct	Sale	2,000	3.44	$6,880.00	257,303	4
2022-05-26	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	2,700	3.52	$9,504.00	178,621	4
2022-05-26	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	4,950	3.51	$17,374.50	259,303	4
2022-05-02	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	400	3.95	$1,580.00	175,921	4
2022-04-08	Kristal, Robert Eugene	Officer	Chief Financial Officer	Direct	Purchase	7,600	5.71	$43,396.00	7,600	4
2022-04-06	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	2,500	5.66	$14,150.00	254,353	4
2022-04-05	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	46,000	5.74	$264,040.00	251,853	4
2022-03-31	Broadrick, Dale	TenPercentOwner	-	Indirect	Purchase	10,700	4.78	$51,146.00	316,972	4
2022-03-21	Broadrick, Dale	TenPercentOwner	-	Direct	Purchase	10,000	4.35	$43,500.00	205,853	4
2022-01-24	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	1,470	3.40	$4,998.00	163,083	4
2022-01-05	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	2,000	3.85	$7,700.00	161,613	4
2021-12-01	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	799	5.50	$4,394.50	159,613	4
2021-11-23	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	2,500	6.00	$15,000.00	158,814	4
2021-11-22	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	396	6.31	$2,498.76	156,314	4
2021-11-19	Silva, Francisco	Director,Officer	VP of Research and Development	Indirect	Purchase	4,000	6.66	$26,640.00	11,829	4
2021-11-16	Alstodt, Lance	Director,Officer	President, CEO, COB	Direct	Purchase	4,500	6.67	$30,015.00	155,918	4
2021-11-16	Silva, Francisco	Director,Officer	VP of Research and Development	Indirect	Purchase	7,826	6.73	$52,668.98	7,829	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

3.82%

Inst. Shares: 677,096

Shares Outstanding: 17,727,747

2025-12-31

3.64%

Inst. Shares: 654,322

Shares Outstanding: 17,986,230

2025-09-30

3.90%

Inst. Shares: 710,322

Shares Outstanding: 18,232,344

2025-06-30

2.69%

Inst. Shares: 470,692

Shares Outstanding: 17,480,764

2025-03-31

2.76%

Inst. Shares: 461,514

Shares Outstanding: 16,714,286

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	677,096	17,727,747	3.82%
2025-12-31	654,322	17,986,230	3.64%
2025-09-30	710,322	18,232,344	3.90%
2025-06-30	470,692	17,480,764	2.69%
2025-03-31	461,514	16,714,286	2.76%
2024-12-31	463,038	15,527,864	2.98%
2024-09-30	439,412	16,242,998	2.71%
2024-06-30	398,548	16,242,998	2.45%
2024-03-31	650,668	20,014,146	3.25%
2023-12-31	552,100	21,091,735	2.62%
2023-09-30	648,814	22,854,215	2.84%
2023-06-30	615,532	23,317,854	2.64%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BioRestorative Therapies, Inc. (BRTX) — SEC Financial Statements & Analysis

BioRestorative Therapies, Inc. (BRTX) is a services-misc health & allied services, nec company, incorporated in NV. BioRestorative Therapies, Inc. trades on Nasdaq as: BRTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BioRestorative Therapies, Inc. reported a -8.47% year-over-year revenue growth, a Gross Profit Margin of 92.09% (TTM), a Debt-to-Equity ratio of 0.53x, a Price-to-Sales (P/S) ratio of 13.48x (TTM), a Price-to-Book (P/B) ratio of 1.59 (TTM), at a market cap of $4.82M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -8.47%
Gross Profit Margin TTM: 92.09%
Debt To Equity: 0.53x
P/S TTM: 13.48x
P/B TTM: 1.59
Market Cap: $4.82M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BioRestorative Therapies, Inc. in?

BioRestorative Therapies, Inc. (BRTX) operates in the Services-Misc Health & Allied Services, NEC industry.

What is BRTX's market cap?

BioRestorative Therapies, Inc. (BRTX) has a market capitalization of $4.82M as of 2026-03-31.

What exchange does BRTX trade on?

BioRestorative Therapies, Inc. (BRTX) trades on the Nasdaq.

Where is BioRestorative Therapies, Inc. incorporated?

BioRestorative Therapies, Inc. is incorporated in NV.

BioRestorative Therapies, Inc. (BRTX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.